Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Acadia Pharmaceutica 12830 El Camino Real Suite 400 SAN DIEGO CA 92130 USA

www.acadia.com Employees: 654 P: 858-558-2871 F: 858-212-0513

Sector:

Medical

Description:

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as'dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.

Key Statistics

Overview:

Market Capitalization, $K 4,498,550
Enterprise Value, $K 4,178,960
Shares Outstanding, K 169,182
Annual Sales, $ 957,800 K
Annual Net Income, $ 226,450 K
Last Quarter Sales, $ 278,630 K
Last Quarter Net Income, $ 71,780 K
EBIT, $ 94,410 K
EBITDA, $ 100,990 K
60-Month Beta 0.68
% of Insider Shareholders 28.30%
% of Institutional Shareholders 96.71%
Float, K 121,304
% Float 71.70%
Short Interest 8,681
Short Float 5.13%
Short Volume Ratio 0.44

Growth:

1-Year Return 47.82%
3-Year Return 36.74%
5-Year Return -49.91%
5-Year Revenue Growth 182.47%
5-Year Earnings Growth 141.88%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.26 on 11/05/25
Next Earnings Date 02/25/26
Earnings Per Share ttm 0.70
EPS Growth vs. Prev Qtr 62.50%
EPS Growth vs. Prev Year 30.00%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ACAD Ratios

Ratio
Price/Earnings ttm 38.26
Price/Earnings forward 38.66
Price/Earnings to Growth 7.12
Return-on-Equity % 14.61%
Return-on-Assets % 9.70%
Profit Margin % 23.64%
Debt/Equity 0.00
Price/Sales 4.26
Price/Cash Flow 37.99
Price/Book 4.94
Book Value/Share 5.42
Interest Coverage -1.75
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar